Clinical trials: Diabetes Type II
Diabetes Mellitus, Type 2
Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes
Evidence regarding optimal methods of insulin dose adjustment is lacking in the literature. The purpose of this study is to evaluate the efficacy and safety of two approaches to escalate prandial insulin therapy in participants…
- Trial name
- AUTONOMY (NCT01215955)
- Testing
- Insulin lispro, Glargine
- Where
- 76 sites in United States, Argentina and 13 more
- Volunteers
- 1,117 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
This is a randomized, double-blind, placebo-controlled, parallel-group, multi-center study to determine the effect of ranolazine when added to glimepiride on glycemic control in adults with type 2 diabetes mellitus (T2DM) who are…
- Trial name
- NCT01494987
- Testing
- Ranolazine, Glimepiride, Diet
- Where
- 140 sites in United States, Czechia and 10 more
- Volunteers
- 431 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years
This study is to assess the efficacy of empagliflozin 10 mg after 52 weeks compared to placebo in elderly patients with Type 2 diabetes mellitus (T2DM) and to explore if empagliflozin has any impact on patient physical condition…
- Trial name
- NCT04531462
- Testing
- Empagliflozin
- Where
- 18 sites in Japan
- Volunteers
- 129 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone
This trial was conducted in Japan. The aim of this trial was to evaluate the safety and efficacy of once daily administration of liraglutide in combination with an oral anti-diabetic drug (OAD) in Japanese subjects with type 2…
- Trial name
- NCT01512108
- Testing
- liraglutide, oral anti-diabetic drug
- Where
- 36 sites in Japan
- Volunteers
- 363 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Clinical Study to Assess the Safety and Pharmacokinetics of SRT2104 in Type 2 Diabetic Human Subjects
The primary purpose of this study is to determine the safety and tolerability of SRT2104 (0.25, 0.5, 1.0, and 2.0 g/day) in type 2 diabetic subjects when administered once daily for 28 consecutive days, and to characterize the…
- Trial name
- NCT00937326
- Testing
- SRT2104
- Where
- 61 sites in Bulgaria, Estonia and 6 more
- Volunteers
- 227 people
- Sponsor
- Sirtris, a GSK Company
Type 2 Diabetes
IGNITE (Impact of Glucose moNitoring and nutrItion on Time in rangE)
The purpose of this study is to learn whether there is a difference in the amount of time glucose (blood sugar) stays within a target range (glucose 70 - 180 mg/dl) when using either continuous glucose monitoring (CGM) or…
- Trial name
- IGNITE (NCT05516797)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- United States
- Volunteers
- 178 people
- Sponsor
- HealthPartners Institute
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Nonalcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
The primary aim of the study is to determine the impact on hepatic steatosis of replacing premeal rapid-acting insulin for exenatide (Byetta) while maintaining bedtime long-acting detemir (Levemir) insulin in well-controlled…
- Trial name
- NCT01006889
- Testing
- Exenatide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Type 2 Diabetes
A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare long-acting basal insulin analog LY2963016 to Lantus® in insulin naïve adult Chinese participants with Type 2 Diabetes Mellitus (T2DM) on 2 or more oral antihyperglycemic medications…
- Trial name
- NCT03338010
- Testing
- LY2963016, Lantus®
- Where
- 32 sites in China
- Volunteers
- 536 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes
Anti-CD3 monoclonal antibody (a.k.a. hOKT3gamma1 [Ala-Ala],teplizumab, MGA031) is a humanized antibody that is commonly used to prevent organ rejection.
- Trial name
- AbATE (NCT00129259)
- Testing
- Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Diabetes, Diabetes Mellitus, Type 2
A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification
Trial comparing effect and safety of insulin degludec/insulin aspart vs. insulin glargine plus insulin aspart in subjects with type 2 diabetes treated with basal insulin with or without oral antidiabetic treatment in need of…
- Trial name
- NCT02906917
- Testing
- Insulin degludec/insulin aspart, Insulin glargine, Insulin aspart
- Where
- 71 sites in United States, Algeria and 5 more
- Volunteers
- 532 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone
The purpose of this study is to evaluate the safety and efficacy of long-term use of pioglitazone/glimepiride combination tablets (Sonias Combination Tablets LD) in patients with type 2 diabetes mellitus who respond poorly to…
- Trial name
- NCT02098746
- Testing
- Pioglitazone/glimepiride
- Volunteers
- 294 people
- Sponsor
- Takeda
Type 2 Diabetes, Coronary Artery Disease
Effects of Linagliptin on Endothelial Function
This study is planned to evaluate if linagliptin can improve endothelial function in patients with type 2 diabetes mellitus. In addition, the effect of linagliptin on arginine bioavailability ratios and postchallenge glycaemic…
- Trial name
- NCT02350478
- Testing
- Linagliptin
- Where
- Austria
- Volunteers
- 49 people
- Sponsor
- Medical University of Graz
Type 2 Diabetes
Adding Sitagliptin or Pioglitazone to Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin and Sulfonylurea
This 24-weeks study will to compare the glycemic efficacy and safety of sitagliptin with pioglitazone in patients with type 2 diabetes who had inadequate glycemic control despite dual therapy with metformin and a sulfonylurea.
- Trial name
- JAS (NCT01195090)
- Testing
- Sitagliptin, pioglitazone
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Sung-Chen Liu
Type 2 Diabetes Mellitus
A Study for Post-Marketing Surveillance of Nesina® Tablet Monotherapy or Combination Therapy in Participants With Type 2 Diabetes (T2DM) in South Korea
The purpose of this study is to evaluate safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not…
- Trial name
- NCT04980040
- Testing
- Alogliptin Benzoate
- Where
- 22 sites in South Korea
- Volunteers
- 3,623 people
- Sponsor
- Takeda
Nonalcoholic Steatohepatitis
Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment
Nonalcoholic fatty liver disease (NAFLD) is a chronic liver condition frequently associated with type 2 diabetes (T2DM) and characterized by insulin resistance and hepatic fat accumulation.
- Trial name
- VA NASH (NCT01002547)
- Testing
- pioglitazone, Vitamin E
- Where
- 2 sites in United States
- Volunteers
- 105 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes, Obesity
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
To determine if the EndoBarrier safely and effectively improves glycemic control in obese subjects with type 2 diabetes
- Trial name
- ENDO (NCT01728116)
- Testing
- EndoBarrier
- Where
- 25 sites in United States
- Volunteers
- 325 people
- Sponsor
- Morphic Medical Inc.
Type 2 Diabetes Mellitus
Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control
A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination with Metformin in Chinese Subjects in China with Type 2 Diabetes…
- Trial name
- NCT02104804
- Testing
- Saxagliptin 5mg
- Where
- 11 sites in China
- Volunteers
- 953 people
- Sponsor
- AstraZeneca
Type 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine
Primary Objective: To demonstrate non-inferiority of SAR341402 versus NovoLog/NovoRapid in glycated hemoglobin A1c (HbA1c) change from baseline to Week 26 in participants with type 1 or type 2 diabetes mellitus (T1DM or T2DM)…
- Trial name
- GEMELLI1 (NCT03211858)
- Testing
- Insulin aspart, NovoLog/NovoRapid, Insulin glargine (HOE901)
- Where
- 82 sites in United States, Finland and 5 more
- Volunteers
- 597 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.